Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Skin Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1500785
This article is part of the Research Topic Management of Rare Oncological Cases View all 57 articles

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy

Provisionally accepted
Chalette Lambert-Swainston Chalette Lambert-Swainston 1Wolfram Samlowski Wolfram Samlowski 2*Brandon Reynolds Brandon Reynolds 3Amin Hedayat Amin Hedayat 4
  • 1 University of Nevada, Las Vegas, Las Vegas, Nevada, United States
  • 2 Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
  • 3 Reynolds Plastic Surgery, Las Vegas, United States
  • 4 Quest Diagnostics, Associated Pathologists Chartered, Las Vegas, United States

The final, formatted version of the article will be published soon.

    Locally advanced basal cell carcinoma (laBCC) remains a significant management challenge. We describe a case of laBCC that recurred after definitive radiotherapy. This patient was treated with neoadjuvant cemiplimab with minimal response. Cautious addition of vismodegib with ongoing cemiplimab treatment was well tolerated and resulted in significant tumor regression. A wide excision demonstrated a pathologic complete response. Further evaluation of cemiplimab and hedgehog inhibitor combination therapy in la BCC appears warranted.

    Keywords: Data curation, Formal analysis, investigation, visualization, Writing -review & editing. Brandon Reynolds: Data curation, Writing -review & editing. Chalette Lambert-Swainston: Conceptualization, methodology, Writing -original draft

    Received: 23 Sep 2024; Accepted: 13 Jan 2025.

    Copyright: © 2025 Lambert-Swainston, Samlowski, Reynolds and Hedayat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wolfram Samlowski, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.